| Company Name: | Targeted Genetics Corporation | | Ticker Symbol: | TGEN | | | WWW Address: | www.targen.com | | CEO: | B.G. Susan Robinson | | No. of Employees: | 58 | | Common Issue Type: | CS | | Business Description: | A clinical-stage biotechnology company, which conducts research and development of gene therapy products and technologies for treating both acquired and inherited diseases.
|
| | | Industry Information: | DRUGS - Biotechnology [more like this] |
|
| Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 0.24 |  0.01 | 0.011 | 0.7 | 0.245 | 0.24 | 0.22 | 33120 |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 5.0 | 20.7 | 2.91 | -1.04 | 0.00 | 0.0 | 0.0 | 0.70 - 0.06 |
|
| KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 0.24 | $ | | PE Ratio - LTM | 0.0 | |
| Market Capitalisation | 5.0 | mil |
| Latest Shares Outstanding | 20.7 | mil |
| Earnings pS (EPS) | -1.04 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | 0 | % |
| Revenue per Employee | 150,310 | $ |
| Effective Tax Rate | 0.0 | % |
| Float | 20.2 | mil |
| Float as % of Shares Outstanding | 97.6 | % |
| Foreign Sales | 0 | mil |
| Domestic Sales | 0 | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 41.50 | % |
| Research & Devlopment (R&D) as % of Revenue | 83.10 | % |
| Gross Profit Margin | 0.0 | % |
| EBITDA Margin | -17.5 | % |
| Pre-Tax Profit Margin | -41.0 | % |
| Assets Turnover | 1.0 | % |
| Return on Assets (ROA) | -102.7 | % |
| Return on Equity (ROE) | 0.0 | % |
| Return on Capital Invested (ROCI) | -170.2 | % |
| Current Ratio | 2.4 | |
| Leverage Ratio (Assets/Equity) | 1.7 | |
| Interest Cover | 0.0 | |
| Total Debt/Equity (Gearing Ratio) | 0.00 | |
| LT Debt/Total Capital | 0.0 | % |
| Working Capital pS | 0.12 | $ |
| Cash pS | 0.19 | $ |
| Book-Value pS | 0.13 | $ |
| Tangible Book-Value pS | 0.13 | $ |
| Cash Flow pS | -0.19 | $ |
| Free Cash Flow pS | -0.26 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 1.81 | |
| Price/Tangible Book Ratio | 1.81 | |
| Price/Cash Flow | -1.3 | |
| Price/Free Cash Flow | -0.9 | |
| P/E as % of Industry Group | 0.0 | % |
| P/E as % of Sector Segment | 0.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | - |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | |
| |
| PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | 4.3 | 103 | 936 | 221 |
| 4 Weeks | 0.28 | 0.20 | 0.21 | 14.3 | 107 | 1,162 | 18,596 |
| 13 Weeks | 0.60 | 0.20 | 0.28 | -14.3 | 80 | 2,665 | 159,886 |
| 26 Weeks | 0.60 | 0.20 | 0.27 | -11.1 | 74 | 2,460 | 305,079 |
| 52 Weeks | 0.70 | 0.06 | 0.26 | -7.7 | 75 | 1,965 | 487,372 |
| YTD | 0.70 | 0.06 | - | 9.1 | 89 | 2,118 | 478,697 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 0.23 | 0.24 | 0.27 | 0.28 | 0.25 | 2.91 | 3.03 |
|
| |
| GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | 4.34 | 22.8 | 3.72 |
| Income | 0.00 | 0.0 | 0.00 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | 9.10 | NA | 24.82 |
| R&D | -7.63 | NA | -11.59 |
| Normalized Inc. | 0.00 | NA | 0.00 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | 40.4 | 113.0 | -15.6 |
| Earnings % | 0.0 | 0.0 | 0.0 |
| EPS % | 0.0 | 0.0 | 0.0 |
| EPS $ | 0.80 | 0.16 | -0.06 |
|
| |
| SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 23.48 |
| Current Ratio | 1.4 |
| Quick Ratio (Acid Test) | 1.4 |
| Liquidity Ratio (Cash) | 1.31 |
| Receivables Turnover | 6.0 |
| Average Collection Period | 60 |
| Working Capital/Equity | -44.5 |
| Working Capital pS | 0.08 |
| Cash-Flow pS | -0.99 |
| Free Cash-Flow pS | -0.54 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | -11.87 |
| Financial Leverage Ratio (Assets/Equity) | 0.0 |
| Debt Ratio | 152.8 |
| Total Debt/Equity (Gearing Ratio) | 0.00 |
| LT Debt/Equity | 0.00 |
| LT Debt/Capital Invested | -183.9 |
| LT Debt/Total Liabilities | 0.0 |
| Interest Cover | 0.0 |
| Interest/Capital Invested | 0.00 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 1.93 |
| Tobin's Q Ratio | 0.69 |
| Current P/E Ratio - LTM | 0.00 |
| Enterprise Value (EV)/EBITDA | -0.91 |
| Enterprise Value (EV)/Free Cash Flow | -0.77 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | 1.81 |
| Price/Book Ratio - LTM | 1.81 |
| Price/Cash Flow Ratio | -1.3 |
| Price/Free Cash Flow Ratio - LTM | -0.9 |
| Price/Sales Ratio | 0.44 |
| P/E Ratio (1 month ago) - LTM | 0.0 |
| P/E Ratio (26 weeks ago) - LTM | 0.0 |
| P/E Ratio (52 weeks ago) - LTM | 0.0 |
| 5-Y High P/E Ratio | 0.0 |
| 5-Y Low P/E Ratio | 0.0 |
| 5-Y Average P/E Ratio | 0.0 |
| Current P/E Ratio as % of 5-Y Average P/E | 0 |
| P/E as % of Industry Group | 0.0 |
| P/E as % of Sector Segment | 0.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 0.0 |
| PER SHARE FIGURES |
| LT Debt pS | 0.00 |
| Current Liabilities pS | 0.19 |
| Tangible Book Value pS - LTM | 0.13 |
| Book Value pS - LTM | 0.13 |
| Capital Invested pS | -0.18 |
| Cash pS - LTM | 0.19 |
| Cash Flow pS - LTM | -0.19 |
| Free Cash Flow pS - LTM | -0.26 |
| Earnings pS (EPS) | -1.04 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | -126.67 |
| Free Cash Flow Margin 5YEAR AVG | -159.68 |
| Net Profit Margin | 0.0 |
| Net Profit Margin - 5YEAR AVRG. | 0.0 |
| Equity Productivity | -2.31 |
| Return on Equity (ROE) | 0.0 |
| Return on Equity (ROE) - 5YEAR AVRG. | 0.0 |
| Capital Invested Productivity | -2.31 |
| Return on Capital Invested (ROCI) | 549.3 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | -89.1 |
| Assets Productivity | 0.50 |
| Return on Assets (ROA) | -289.8 |
| Return on Assets (ROA) - 5YEAR AVRG. | -60.7 |
| Gross Profit Margin | 0.0 |
| Gross Profit Margin - 5YEAR AVRG. | 0.0 |
| EBITDA Margin - LTM | -17.5 |
| EBIT Margin - LTM | -41.0 |
| Pre-Tax Profit Margin | 0.0 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 0.0 |
| Effective Tax Rate | 0.0 |
| Effective Tax Rate - 5YEAR AVRG. | 0.0 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 13 |
| Revenue per Employee | 150,310 |
| Net Income per Employee | -357,241 |
| Average Collection Period | 13 |
| Receivables Turnover | 6.0 |
| Day's Inventory Turnover Ratio | 0 |
| Inventory Turnover | 0.0 |
| Inventory/Sales | 0.0 |
| Accounts Payble/Sales | 19.90 |
| Assets/Revenue | 2.00 |
| Net Working Capital Turnover | 5.19 |
| Fixed Assets Turnover | 5.87 |
| Total Assets Turnover | 0.5 |
| Revenue per $ Cash | 1.67 |
| Revenue per $ Plant | 6.78 |
| Revenue per $ Common Equity | -2.31 |
| Revenue per $ Capital Invested | -2.31 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 66.8 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 70.9 |
| Research & Devlopment (R&D) as % of Revenue | 174.2 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 174.2 |
|
|  
|
| |
 |  |